Leerink Partnrs Has Negative View of 908 Devices Q3 Earnings

Key Points

• Leerink Partners has downgraded its Q3 2025 earnings estimate for 908 Devices to ($0.15) per share, down from ($0.14), while maintaining a "Strong-Buy" rating on the stock.
• In its most recent quarterly earnings report, 908 Devices reported an EPS of ($0.18), which was below the consensus estimate of ($0.16), along with revenue of $4.70 million, significantly lower than the expected $12.17 million.
• Institutional investors have shown significant interest in 908 Devices, with AWM Investment Company Inc. increasing its stake by 210.6% in the first quarter of this year.

908 Devices Inc. (NASDAQ:MASS - Free Report) - Equities researchers at Leerink Partnrs lowered their Q3 2025 earnings estimates for shares of 908 Devices in a report issued on Monday, October 13th. Leerink Partnrs analyst P. Souda now forecasts that the company will post earnings per share of ($0.15) for the quarter, down from their previous forecast of ($0.14). Leerink Partnrs has a "Strong-Buy" rating on the stock. The consensus estimate for 908 Devices' current full-year earnings is ($1.99) per share. Leerink Partnrs also issued estimates for 908 Devices' Q4 2025 earnings at ($0.08) EPS and FY2025 earnings at ($0.62) EPS.

908 Devices (NASDAQ:MASS - Get Free Report) last released its quarterly earnings results on Tuesday, August 5th. The company reported ($0.18) EPS for the quarter, missing analysts' consensus estimates of ($0.16) by ($0.02). 908 Devices had a negative return on equity of 24.30% and a negative net margin of 30.54%.The company had revenue of $4.70 million for the quarter, compared to the consensus estimate of $12.17 million. 908 Devices has set its FY 2025 guidance at EPS.

MASS has been the topic of a number of other reports. Weiss Ratings reiterated a "sell (d-)" rating on shares of 908 Devices in a report on Wednesday, October 8th. Leerink Partners raised shares of 908 Devices from a "market perform" rating to an "outperform" rating and set a $12.00 target price on the stock in a research report on Tuesday, August 5th. Finally, Wall Street Zen raised shares of 908 Devices from a "sell" rating to a "hold" rating in a research report on Monday, September 15th. One research analyst has rated the stock with a Strong Buy rating, three have issued a Buy rating and one has given a Sell rating to the company. Based on data from MarketBeat, 908 Devices presently has an average rating of "Moderate Buy" and an average price target of $8.00.

908 Devices Price Performance

NASDAQ MASS opened at $8.60 on Thursday. The company's 50 day simple moving average is $6.99 and its 200 day simple moving average is $6.26. 908 Devices has a 12 month low of $1.81 and a 12 month high of $9.22. The company has a market capitalization of $308.40 million, a P/E ratio of -15.93 and a beta of 0.46.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently added to or reduced their stakes in the stock. AWM Investment Company Inc. grew its position in 908 Devices by 210.6% in the first quarter. AWM Investment Company Inc. now owns 5,199,924 shares of the company's stock worth $23,296,000 after acquiring an additional 3,526,000 shares in the last quarter. First Light Asset Management LLC bought a new stake in 908 Devices in the first quarter worth approximately $7,621,000. GM Advisory Group LLC bought a new stake in 908 Devices in the second quarter worth approximately $8,309,000. Invesco Ltd. bought a new stake in 908 Devices in the first quarter worth approximately $2,910,000. Finally, Marshall Wace LLP grew its position in 908 Devices by 359.4% in the second quarter. Marshall Wace LLP now owns 648,796 shares of the company's stock worth $4,626,000 after acquiring an additional 507,562 shares in the last quarter. 88.06% of the stock is owned by hedge funds and other institutional investors.

Insider Buying and Selling

In related news, CFO Joseph H. Iv Griffith sold 5,000 shares of the business's stock in a transaction that occurred on Friday, September 19th. The shares were sold at an average price of $7.07, for a total transaction of $35,350.00. Following the transaction, the chief financial officer directly owned 97,930 shares of the company's stock, valued at approximately $692,365.10. The trade was a 4.86% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through the SEC website. Insiders have sold 10,000 shares of company stock worth $80,593 over the last quarter. Insiders own 23.70% of the company's stock.

908 Devices Company Profile

908 Devices Inc, a commercial-stage technology company, provides various purpose-built handheld and desktop mass spectrometry devices to interrogate unknown and invisible materials in life sciences research, bioprocessing, pharma/biopharma, forensics, and adjacent markets. The company's products include MX908, a handheld, battery-powered, and Mass Spec device that is designed for rapid analysis of solid, liquid, vapor, and aerosol materials of unknown identity; Rebel, a small desktop analyzer that provides real-time information on the extracellular environment in bioprocesses; and Maverick, an optical in-line analyzer that offers real-time monitoring and control of multiple bioprocess parameters, including glucose, lactate, and total biomass in mammalian cell cultures, as well as provides process fingerprint data to support large-scale efforts in predictive bioprocess modeling.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.